big pharma en voeding


logo.jpg (7231 bytes)

Google

Deze pagina is verouderd - ontvang onze nieuwtjes per email

 

Big pharma


U.S. psychiatrists to end drug company seminars

The American Psychiatric Association said on Wednesday it will end medical education seminars and meals sponsored by drug companies at its annual meetings to reduce chances for financial conflicts of interest.

Lees verder

Leendert

--

Ik wil nog even kwijt dat dit soort praktijken in ons land gewoon nog plaats vinden. Glaxosmithkline bijvoorbeeld op 2 oktober in Bussum het Bussum Symposium Psychiatrie. Onder het mom van nieuwe behandelmodaliteiten in de psychiatrie proberen natuurlijk gewoon hun handel te slijten.

Ron


Indonesia reconsiders vaccinations for children, citing mistrust of drug companies

Indonesia's controversial health minister says she wants to end vaccinating children against meningitis, mumps and some other diseases because she fears foreign drug companies are using the country as a testing ground.

Lees verder

Leendert


Vioxx maker Merck and Co drew up doctor hit list

AN international drug company made a hit list of doctors who had to be "neutralised" or discredited because they criticised the anti-arthritis drug the pharmaceutical giant produced. Staff at US company Merck &Co emailed each other about the list of doctors - mainly researchers and academics - who had been negative about the drug Vioxx or Merck and a recommended course of action.

Lees verder

Leendert


AstraZeneca tried to 'bury' bad news on Seroquel drug

AstraZeneca tried to “bury” adverse medical studies about Seroquel, its blockbuster drug, internal company memos released in an American court case have revealed.

Link


Seroquel, Sex And Major Conflicts Of Interest Between AstraZeneca Exec And British Researcher, US Ghostwriter

There's been much news of conflict of interest between pharmaceutical companies and outside researchers possibly biasing the results of studies of psychiatric drugs over the last year. Notably, Sen. Charles Grassley (R-Iowa) has exposed researchers at Harvard University, Emory University and George Washington University, among others, as being locked in questionable alliances with companies such as Johnson & Johnson and GlaxoSmithKline.

Link




Make a killing - de handel in mentale ziekten

Deel 2

Deel 3


De handel in kanker

Das Geschäft mit dem Krebs

Überteuerte Medikamente, Rabatte für Krankhäuser oder finanzielle Unterstützung für behandelnde Mediziner - wie die Pharma-Branche und Ärzte abkassieren.


Pittige kritiek op farmareuzen

Geneesmiddelfabrikanten deelden bij de marketing van cholesterolpillen cadeaus uit aan artsen, om hun voorschrijfgedrag te beïnvloeden. Pfizer en AstraZeneca, de producenten van de cholesterolpillen Lipitor en Crestor, hebben met hun marketing de grenzen opgezocht. En soms ook overschreden. Dit blijkt uit twee onderzoeksrapporten van de Inspectie voor de Gezondheidszorg (IGZ).

Bron: Trouw


Ongeoorloofde reclame farmaceutische industrie hard aanpakken

SP-Kamerlid Henk van Gerven vindt dat er een eind moet komen aan de ongeoorloofde reclamepraktijken van de farmaceutische industrie. Hij wil dat minister Klink (Volksgezondheid) ingrijpt, nu uit onderzoek van de Inspectie voor de Gezondheidszorg (IGZ) blijkt dat farmareuzen Pfizer en AstraZeneca de reclameregels hebben overtreden. De Inspectie maakt melding van het weggeven van espresso-apparaten en draadloze toetsenborden, twijfelachtige onderzoeken en overmatige vergoedingen aan artsen. Van Gerven: "Er moet een eind worden gemaakt aan de beïnvloeding van artsen om bepaalde medicijnen voor te schrijven. Dit kost de samenleving miljoenen euro's per jaar."


Big pharma, wetenschappers en belangenverstrengeling

Mooi voorbeeld van de rol van wetenschappers zoals Ron Herings met verstrengelde belangen richting
big pharma en die dit verzwijgen in wetenschappelijke publicaties:

http://weblogs.vpro.nl/argos/2008/06/06/
http://lib.bioinfo.pl/auth:Herings,R
http://mikscommunicatienotities.blogspot.com/2008/02/
http://worldthechanges.wordpress.com/gezondheid/
http://www.ublad.uu.nl/WebObjects/UOL.woa/4/wa/Ublad?id=1031585

 

Een mooi voorbeeld van die nauwe banden:

The research was funded by an unrestricted grant from Nefarma -- the Dutch association of pharmaceutical industries. But, the study was designed, conducted and analysed entirely independently of the funders.

http://www.sciencedaily.com/releases/2006/12/061207160618.htm

 

Heel grappig is dat juist Herings weer kritiek heeft op de banden tussen big pharma en universiteiten:

Ook dr. Ron Herings van de faculteit Farmacie kan meepraten over de soms moeizame relatie met opdrachtgevers. Als epidemioloog doet hij in opdracht van zowel bedrijven als overheidsinstellingen onderzoek naar de werkzaamheid en de veiligheid van geneesmiddellen. Een aantal maanden geleden was Herings in het nieuws omdat hij ontdekt had dat de derde generatie anti-conceptie pil van Organon bij bepaalde groepen vrouwen een verhoogd risico op vaat-vernauwingen met zich meebracht. Organon was not amused, vertelt Herings. "Na die publicatie in the Lancet merkte ik pas hoe universiteitsbreed sommige belangen zijn. Een Utrechtse vakgroep bleek voor een groot deel afhankelijk te zijn van financiering door Organon. Als dat bedrijf zich zou terugtrekken uit alle onderzoek zou dat dus grote problemen opleveren voor die mensen. Het is eigenlijk te gek voor woorden dat een individuele onderzoeker dingen kan opschrijven met zoveel invloed. De universiteit zou in dit soort situaties, vind ik, meer steun moeten verlenen aan onderzoekers. We zouden eens naar de Verenigde Staten moeten kijken. Daar verloopt alle communicatie tussen de industrie en een universiteit via een speciaal bureau."

http://www.ublad.uu.nl/WebObjects/UOL.woa/4/wa/Ublad/archief?id=1013767


Drugs industry protecting ‘morally unacceptable’ patent system

Major drugs companies are using fierce lobbying tactics to protect a pharmaceutical patent system that is “simply morally unacceptable”, a world-leading political philosopher will tell a major meeting of UK and European pharmacologists today Addressing an audience that will include senior figures from the pharmaceutical industry, Thomas Pogge, Professor of Philosophy and International Affairs at Yale University in the United States, will argue that international rules on intellectual property “violate the human rights of poor people by denying them access to vital medicines”. He will go on to say that huge mortality and morbidity rates can be dramatically lowered by reforming the way the development of new medical treatments is funded.

In his AstraZeneca-sponsored lecture entitled, 'Advanced Medicines: Must We Exclude the Global Poor?', Pogge will propose an alternative licensing system called the Health Impact Fund (HIF) which he says is “required as an add-on to the existing system to render it human-rights compliant”. The HIF would be a global agency, says Pogge, underwritten by governments. It would offer to reward the patentee of any new medicine, during its first decade or so, with annual payments proportional to this medicine’s demonstrated global health impact. Registering a medicine with the Fund would be voluntary and require a concession affecting its price. Pogge says this would give innovators the opportunity to forgo “monopoly rents in favour of an alternative path that would provide ample rewards for the development of new high-impact medicines without excluding the poor from their use”.

Pogge will deliver his AstraZeneca-sponsored lecture on the final day of the Federation of European Pharmacological Societies (EPHAR) 2008 Congress, hosted by the British Pharmacological Society at The University of Manchester. Speaking ahead of his lecture, Pogge said: “The main responsibility for change lies with politicians and citizens. But pharmaceutical companies are also citizens, and they play a significant role in the political process of most societies. They lobby a lot. And here I do see fault. They lobby for holding the line on a status quo that is simply morally unacceptable.  “They do this because they know the existing rules can have a profitable business model under them and are uncertain what alternative rules would be settled upon once the existing rules were found unacceptable.  “I want to change this conservative attitude. I want to give them an institutional reform that they can endorse and unite behind. I am convinced they would do better, on the whole, with the Health Impact Fund than without. I want to convince them of this. And I want to show them that, on balance, they have more to gain than to lose by supporting this reform.  “It will be harder and harder to hold the line on the existing system, and the HIF reform preserves pretty much everything they like about this system. In other words, they have both moral and strategic reasons to support the HIF.”

Pogge’s lecture is expected to provoke fierce debate at the conference, with many delegates holding alternative views.


The Truth About Drug Companies

Marcia Angell exposes the research and spending habits of the world's top pharmaceutical companies.

Hele video, 52min : http://videos.med.wisc.edu/videoInfo.php?videoid=940


Big pharma - lobbyisten

Ik kwam nog een verslag mbt big pharma in de VS tegen waaruit oa blijkt dat er in 2002 voor elke senator 7 lobbyisten aktief waren:

The drug industry hired 675 different individual lobbyists from 138 firms in 2002. That’s nearly seven lobbyists for each U.S. Senator.

en dat er in 2001 2.7 miljard dollar in advertenties is gestoken met voor iedere uitgegeven dollar aan consumenten advertenties er weer 4.20 dollar verkoop tegenover stond:

A Harvard-MIT study released in 2003 determined that direct-to-consumer advertising by the drug industry increased from $800 million in 1996 to $2.7 billion in 2001.21 Measured purely by profits, it is easy to see why pharmaceuticals are sold on advertising: The Harvard-MIT study found that for every dollar spent on direct-to-consumer ads, the companies achieved $4.20 in sales.

http://www.citizen.org/documents/Pharma_Report.pdf

Ron


The false gods of scientific medicine revealed

Promoters of conventional medicine claim that all the drug marketing, FDA approvals, surgical procedures, chemotherapy and all other treatments are based on "hard science." The term "science" is invoked with hilarious frequency: Science journals, science-based medicine, proven medical science and so on. As you might have guessed, however, there's surprisingly little genuine science to be found in the common practice of conventional medicine. Rather, what passes for "science" today is a collection of health myths, half-truths, intellectual dishonesty, self delusion, fraudulent reporting and wishful thinking.

http://www.newstarget.com/021922.html


Video - Marketing Disease and Pushing Drugs


Pharmaceutical compounds found in nation's fresh water

According to a study in the May/June 2007 issue of the journal Ground Water, pharmaceuticals are being found in septic tanks and, consequentially, ground water due to incomplete human metabolism and excretion into the waste stream or by disposal of unused medications in the toilet or down the sink.

http://www.blackwellpublishing.com/press/pressitem.asp?ref=1211


Physician ties to drug industry stronger than ever

Despite the potential for conflict of interest, virtually all practicing physicians in the U.S. have some form of relationship with pharmaceutical manufacturers but the nature and extent of those relationships vary, depending on the kind of practice, medical specialty, patient mix, and professional activities, reports a study in the April 26 issue of the New England Journal of Medicine.

In the first national survey to gauge the predictors and depth of relationships between industry and practicing physicians, 94 percent of doctors report that they have at least one type of relationship with the drug industry, mostly in the form of receiving food in the workplace or prescription samples. However, more than one third are reimbursed for costs associated with professional meetings or continuing medical education (CME), and more than a quarter receive honoraria for consulting, lecturing or enrolling patients in clinical trials, say researchers at Massachusetts General Hospital-Partners Health Care System, Yale University, and the University of Melbourne and Royal Melbourne Hospital in Australia.

"Relationships with industry are a fundamental part of the way medicine is practiced today. The real questions relate to how much is too much and how far is too far. It appears that these relationships benefit physicians and industry but the important policy question is to what extent do these relationships benefit patients in the terms of the care they receive," says lead researcher and co-author Eric Campbell, Ph.D., an associate professor of medicine at the Institute for Health Policy at Massachusetts General Hospital and Harvard Medical School.

The findings, from a survey of 1,662 practicing physicians conducted in late 2003 and 2004, also show that drug and device manufacturers pick and choose which doctors to form the strongest ties with. For example, cardiologists are more than twice as likely as family practitioners to receive direct payments from drug companies for consulting and other services and are also significantly more likely to be paid honoraria than pediatricians, anesthesiologists, or surgeons. "Cardiology is a highly influential specialty within the medical profession. If the drug and device industry can influence cardiologists, they can likely influence the prescribing practices of other doctors," says Campbell.

http://www.eurekalert.org/pub_releases/2007-04/bc-ptt042507.php


How a drug's risks emerge

How can big safety issues go undetected in medicines taken by millions of people for many years, as happened this week with the diabetes pill Avandia and a few years ago with the painkiller Vioxx?

http://seattlepi.nwsource.com/health/1500AP_Risky_Drugs_Analysis.html


U.S. Senators financially enslave Americans as Indentured Servants to Big Pharma

The facts found in the report are almost as astonishing as the source of the report itself: USA Today, a mainstream media giant in the United States, has revealed the apparent financial conflict of interest by U.S. Senators who voted against the infamous S.1082 reimportation amendment. That amendment would have ended Big Pharma's monopoly over U.S. consumers and ultimately saved American citizens, businesses and governments tens of millions of dollars by allowing them to import medicines from other nations with approved safety records (such as Canada or Japan).

http://www.newstarget.com/021853.html


Big Pharma Targets Women For Drugs They Don't Need

Selling anxiety sells medicine. Drug companies know this and profit by it. But are women benefiting as much as the industry's bottom line?

http://www.alternet.org/healthwellness/52230/


Physician ties to drug industry stronger than ever

Despite the potential for conflict of interest, virtually all practicing physicians in the U.S. have some form of relationship with pharmaceutical manufacturers but the nature and extent of those relationships vary, depending on the kind of practice, medical specialty, patient mix, and professional activities, reports a study in the April 26 issue of the New England Journal of Medicine. In the first national survey to gauge the predictors and depth of relationships between industry and practicing physicians, 94 percent of doctors report that they have at least one type of relationship with the drug industry, mostly in the form of receiving food in the workplace or prescription samples. However, more than one third are reimbursed for costs associated with professional meetings or continuing medical education (CME), and more than a quarter receive honoraria for consulting, lecturing or enrolling patients in clinical trials, say researchers at Massachusetts General Hospital-Partners Health Care System, Yale University, and the University of Melbourne and Royal Melbourne Hospital in Australia.

http://www.eurekalert.org/pub_releases/2007-04/bc-ptt042507.php


Drug company sales visits influenced doctors, study finds

Almost half of sales visits by pharmaceutical company representatives advocating the use of the drug gabapentin led to doctors stating that they intended to increase their prescription of the drug or recommend it to colleagues, according to an analysis of a survey completed by the doctors shortly after the visits.

http://pub.ucsf.edu/newsservices/releases/200704194/


Drug reps use friendship to influence doctors

In a unique collaborative paper in PLoS Medicine, a former drug rep and a physician who researches drug marketing reveal the tactics used by drug reps to manipulate physicians into selling drugs.

"Drug reps increase drug sales by influencing physicians, and they do so with finely titrated doses of friendship," say the authors, Adriane Fugh-Berman (Georgetown University Medical Center) and Shahram Ahari, a former drug rep for Eli Lilly who now works for the School of Pharmacy at University of California San Francisco.

The specific strategy used by a drug rep to manipulate a physician, say the authors, depends very much on the personality of the doctor. A friendly, outgoing physician is the easiest to influence, because the rep can use the "friendship" to request favors, in the form of prescriptions. If a physician refuses to meet with a rep, "their staff is dined and flattered in hopes that they will act as emissaries for a rep's message." Physicians who end up prescribing the rep's drugs are amply rewarded with gifts, such as golf bags or silk ties.

http://www.eurekalert.org/pub_releases/2007-04/plos-dru041907.php


Pharmaceutical industry creates diseases

According to Lockett, the pharmaceutical industry creates diseases. He said that conditions that were not considered diseases years ago, are now treated with medication – like insomnia, attention-deficit hyperactivity disorder, cholesterol and anxiety.

http://www.mineralwellsindex.com/local/local_story_194101609.html


Big Pharma takes over veterinary medicine; dogs and cats drugged with chemicals for profit

Big Pharma has successfully completed its takeover of veterinary medicine in the United States and other first-world nations. Knowing that massive profits could be generated through the bodies of pets, drug companies have spent two decades pursuing an aggressive campaign of rewriting vet school curricula, influencing veterinarians and brainwashing pet owners into thinking their dogs, cats and horses need drugs in order to be healthy. It was an easy sell: Most consumers already demonstrate a cult-like belief in pharmaceutical medicine thanks to a barrage of direct-to-consumer advertising funded by deep-pocketed drug companies, and it was only a minor shift to get them to believe animals need synthetic chemicals in their bodies, too.

http://www.newstarget.com/021935.html


Experts call for urgent research into anti-epileptic drugs given to children

Researchers have discovered a five-fold increase in newer anti-epileptic drugs given to children, despite the fact that their long-term safety has not been established. They've now called for urgent research into the top three. This comes hard on the heels of a report by the European Medicines Agency, which highlighted the need for further research into 21 anti-epileptic drugs for children but didn't state which ones should be prioritized.

http://www.eurekalert.org/pub_releases/2007-06/bpl-ecf060707.php


A frightening industry proposal

Anonymised data use for adverse events surveillance is one thing; non-anonymised data to identify potential trial candidates, presumably followed by a direct approach to invite them to join a drug trial, are another matter entirely.

http://www.bmj.com/cgi/content/extract/334/7606/1236-c


When it comes to food and drugs, following the money is good advice

The FDA is still struggling with safety issues. Until it is adequately funded so that it can monitor ingredients from places as far away as China, Americans will wonder about the safety of their food and drug supply.

http://www.chron.com/disp/story.mpl/life/4877878.html


 

 


 


View My Stats